**7. Conclusion**

The clinical trials of Convalescent plasma therapy conducted/initiated against SARS-CoV-2 pandemic across the world are getting increased day-by-day due to the *Convalescent Plasma Immunotherapy - A Possible Mitigation Strategy for SARS-CoV-2 Pandemic DOI: http://dx.doi.org/10.5772/intechopen.98254*

significant outcomes of infected patients with a high positive recovery rate when compared to all other modes of treatment against SARS-CoV-2 pandemic crisis. In SARS-CoV-2, many reports have shown that administration of CP immunotherapy is safe with significant potential efficacy and it was not associated with any major adverse events. Even in the autoimmune conditions also CP is considered to be safe. Thus, CP immunotherapy is considered as classical and historically noteworthy candidate to be further re-evaluated as a most suitable therapeutic option against SARS-CoV-2 pandemic.
